Abstract
Background
M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A (THSD7A) have recently been identified as target antigens for patients with idiopathic membranous nephropathy (IMN). The prevalence of PLA2R and THSD7A in the serum of MN patients deserves further investigation.
Methods
Here, we studied the presence of anti-PLA2R and anti-THSD7A antibodies in patients with biopsy-proven IMN (n = 212), secondary membranous nephropathy (SMN, n = 118), and other kidney diseases (n = 84). The progress of 49 IMN patients [anti-PLA2R(+), n = 27; anti-THSD7A(+), n = 6; anti-PLA2R(−) and anti-THSD7A(−) dual negative, n = 16] who received immunosuppressive therapy was observed for 12 months. Serum concentrations of antibodies against PLA2R and THSD7A were detected using an indirect immunofluorescent assay.
Results
One hundred fifty-two (71.7%) IMN patients and 11 (9.3%) SMN patients were identified as anti-PLA2R(+) anti-THSD7A(−). Five (2.4%) IMN patients and two (1.7%) SMN patients were identified as anti-THSD7A(+) anti-PLA2R(−). One of the IMN patients was identified as anti-PLA2R(+) and anti-THSD7A(+). The rate of partial remission was lower in anti-PLA2R(+) patients than in anti-PLA2R(−) patients 3 months (P = 0.045) and 6 months (P = 0.006) after immunosuppressive therapy. The rate of complete remission was lower in anti-PLA2R(+) patients than in anti-PLA2R(−) patients 12 months (P = 0.037) after immunosuppressive therapy.
Conclusions
The serum concentration of anti-PLA2R antibodies may be used as a sensitive and specific marker for diagnosing IMN. Immunosuppressive therapy is more effective for IMN patients who are anti-PLA2R(−) than for those who are anti-PLA2R(+).
Similar content being viewed by others
References
Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H (2013) Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant 28:1839–1844
Ma H, Sandor DG, Beck LH (2013) The role of complement in membranous nephropathy. Semin Nephrol 33:531–542
Rozenberg I, Kotliroff A, Zahavi T, Benchetrit S (2018) Outcome of idiopathic membranous nephropathy: a retrospective study. Isr Med Assoc J 20:186–189
Murtas C, Ghiggeri GM (2016) Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms. J Nephrol 29:469–478
Fresquet M, Jowitt TA, Gummadova J et al (2015) Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol 26:302–313
Beck LH, Bonegio RG, Lambeau G et al (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11–21
Radice A, Trezzi B, Maggiore U et al (2016) Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmun Rev 15:146–154
Tomas NM, Beck LH, Meyer-Schwesinger C et al (2014) Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371:2277–2287
Iwakura T, Ohashi N, Kato A, Baba S, Yasuda H (2015) Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy. PLoS One 10:e0138841
Larsen CP, Cossey LN, Beck LH (2016) THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Mod Pathol 29:421–426
L’Imperio V, Pieruzzi F, Sinico RA et al (2018) Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain. J Nephrol 31:543–550
Hoxha E, Harendza S, Zahner G et al (2011) An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26:2526–2532
Qin W, Beck LH, Zeng C et al (2011) Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 22:1137–1143
Akiyama S, Akiyama M, Imai E, Ozaki T, Matsuo S, Maruyama S (2015) Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol 19:653–660
Gopalakrishnan N, Abeesh P, Dineshkumar T et al (2016) Prevalence of serum anti M-type phospholipase A2 receptor antibody in primary membranous nephropathy: a single center experience. Indian J Nephrol 26:257–261
Hofstra JM, Debiec H, Short CD et al (2012) Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 23:1735–1743
Dai H, Zhang H, He Y (2015) Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Sci Rep 5:8803
Ronco P, Debiec H (2012) Pathogenesis of membranous nephropathy: recent advances and future challenges. Nat Rev Nephrol 8:203–213
Knehtl M, Debiec H, Kamgang P et al (2011) A case of phospholipase A2 receptor-positive membranous nephropathy preceding sarcoid-associated granulomatous tubulointerstitial nephritis. Am J Kidney Dis 57:140–143
Larsen CP, Messias NC, Silva FG, Messias E, Walker PD (2013) Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 26:709–715
Ge YC, Jin B, Zeng CH et al (2016) PLA2R antibodies and PLA2R glomerular deposits in psoriasis patients with membranous nephropathy. BMC Nephrol 17:185
Sharma SG, Larsen CP (2018) Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol 31:616–622
Wang J, Cui Z, Lu J et al (2017) Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy. Clin J Am Soc Nephrol 12:1642–1651
Hayashi N, Okada K, Matsui Y et al (2018) Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy. Nephrol Dial Transplant 33:832–840
Hoxha E, Wiech T, Stahl PR et al (2016) A mechanism for cancer-associated membranous nephropathy. N Engl J Med 374:1995–1996
Li X, Wei D, Zhou Z et al (2016) Anti-PLA2R antibodies in Chinese patients with membranous nephropathy. Med Sci Monit 22:1630–1636
Acknowledgements
This work was granted by the Foundation of Health and Family Planning Commission of Hubei province (Grant no. WJ2017M217).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (the Ethics Committee of Hubei University of Medicine) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tian, C., Li, L., Liu, T. et al. Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy. Int Urol Nephrol 51, 1371–1377 (2019). https://doi.org/10.1007/s11255-019-02146-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-019-02146-w